Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial.
Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L, Mao Y, Tan F, Gao Y, Wu N, Ying J, Xue Q, Li N, Gao S, He J.
Zhao J, et al. Among authors: li n, li l.
J Thorac Oncol. 2023 Jun;18(6):780-791. doi: 10.1016/j.jtho.2023.02.019. Epub 2023 Mar 2.
J Thorac Oncol. 2023.
PMID: 36870519
Free article.
Clinical Trial.